Luca Richeldi

Università Cattolica del Sacro Cuore — Italy

Medicine · Health Sciences

92h-index57.5kcitations710works6.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis(444), Sarcoidosis and Beryllium Toxicity Research(127), Medical Imaging and Pathology Studies(76), Tuberculosis Research and Epidemiology(72), Pulmonary Hypertension Research and Treatments(65)

Publications703 total

Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON)
BMC Pulmonary Medicine·2025Open Access
Impact of Dosing on Functional and Clinical Outcomes of Patients With Progressive Pulmonary Fibrosis Treated With Nintedanib: Data From a Real-World, Multicentric, Italian Study
Archivos de Bronconeumología·2025Open Access
Bronchial hyper-reactivity impacts symptoms in severe eosinophilic asthmatic patients
2025
Late Breaking Abstract - Effect of nerandomilast on clinical outcomes in patients with progressive pulmonary fibrosis (PPF): results from the final database lock of the FIBRONEER-ILD trial
2025
Effect of nerandomilast in subgroups of patients with idiopathic pulmonary fibrosis (IPF) in the FIBRONEER-IPF trial
2025
The TRITRIAL study: the improvement of CAT according to COPD severity
2025
Artificial Intelligence-analyzed airway parameters and disease progression in fibrotic Hypersensitivity Pneumonitis
2025
Can AI convey empathy? A comparative analysis with physicians
2025
Does FEV1 stability tell us everything about lung function in asthma remission?
2025
Residential Course Learning vs. AI Responses with ChatGPT: Comparative Study of Knowledge Acquisition
2025
Effectiveness of Nintedanib in progressive pulmonary fibrosis assessed by progression criteria. An Italian, observational, multicentre study.
2025
Late Breaking Abstract - Safety and tolerability of nerandomilast in patients with pulmonary fibrosis: pooled data from the FIBRONEER-IPF and FIBRONEER-ILD trials
2025
Watching an Evolution in Progress, Cutting-Edge Research Transforming Outcomes in Interstitial Lung Disease: Introduction to an <i>AJRCCM</i> Special Section
American Journal of Respiratory and Critical Care Medicine·2025Open Access
Standardized Clinical Terms and Definitions for Interstitial Lung Disease: A Consensus Statement from the Fleischner Society
American Journal of Respiratory and Critical Care Medicine·2025· 2 cited
Medical Thoracoscopy With vs Without Prior Artificial Pneumothorax for Patients With Minimal or Absent Pleural Effusion
CHEST Journal·2025· 5 cited
Air pollution and alveolar health
European Respiratory Review·2025· 2 citedOpen Access
Best Practice: International Multisociety Consensus Statement for Post–COVID-19 Residual Abnormalities on Chest CT Scans
Radiology·2025· 5 cited
Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement
American Journal of Respiratory and Critical Care Medicine·2025· 38 citedOpen Access
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
New England Journal of Medicine·2025· 73 citedOpen Access
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
New England Journal of Medicine·2025· 88 citedOpen Access
page 1 of 36Next →

Frequent Co-authors

Athol U. Wells(19), Harold R. Collard(17), Ganesh Raghu(16), Kevin M. Brown(13), Yoshikazu Inoue(13), Christopher J. Ryerson(13), Vincent Cottin(12), Fernando J. Martínez(11), Susanne Stowasser(11), Moisés Selman(10), Ulrich Costabel(9), Martin Kolb(9), Kevin Flaherty(8), David A. Lynch(8), David M. Hansell(8), Andrew G. Nicholson(8), Jürgen Behr(7), Takeshi Johkoh(7), Jeffrey L. Myers(6), Rozsa Schlenker‐Herceg(6)